Stay updated on T-VEC + Pembrolizumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page.

Latest updates to the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page
- Check8 days agoChange DetectedResults have been posted on 2025-10-29, including the Best Objective Response Rate (CR + PR) per RECIST 1.1 and the associated results submission dates. The Study Protocol and Statistical Analysis Plan PDF (dated 2024-07-22) was added to Study Documents.SummaryDifference1%

- Check15 days agoChange DetectedTwo screenshots show the same study page with no significant changes to core content (eligibility, interventions, outcomes, or locations); any differences are limited to formatting and date updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check36 days agoChange Detected- Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.SummaryDifference3%

- Check44 days agoChange DetectedCore content status updated: results moved fromSummaryDifference0.2%

- Check58 days agoChange DetectedThe page version was updated from v3.0.1 to v3.0.2 and the Back to Top link was removed; no core content or time-sensitive information was altered.SummaryDifference0.2%

- Check65 days agoChange DetectedThe web page has been updated from version v3.0.0 to v3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%

Stay in the know with updates to T-VEC + Pembrolizumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-VEC + Pembrolizumab in Sarcoma Clinical Trial page.